Baseline and 6-month changes in patient-reported outcomes*
| Baseline | Δ6 months crude data | Δ6 months adjusted analysis† | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PsA (n=430) | RA (n=1218) | p Value | PsA (n=330) | RA (n=929) | p Value | PsA‡ (n=330) | RA‡ (n=929) | p Value | |
| Patient global VAS (0–100 mm) | 51.5±20.9 51 (37–67) | 49.0±24.0 48 (31–68) | 0.04§ | −12.8 (−15.4 to −10.1) | −13.8 (−15.5 to −12.1) | 0.54§ | −10.7 (−13.1 to −8.3) | −14.5 (−15.9 to −13.1) | 0.009 |
| Joint pain VAS (0–100 mm) | 48.6±21.4 48 (32–65) | 47.3±24.0 46 (28–67) | 0.28§ | −12.2 (−15.0 to −9.5) | −14.4 (−16.0 to −12.7) | 0.20§ | −10.3 (−12.7 to −8.0) | −15.0 (−16.4 to −13.6) | 0.001 |
| Fatigue VAS (0–100 mm) | 45.5±28.6 46 (22–70) | 43.9±29.1 45 (17–68) | 0.37¶ | −0.9 (−3.9 to 2.1) | −4.6 (−6.5 to −2.7) | 0.05§ | 0.1 (−2.7 to 2.9) | −4.9 (−6.6 to −3.3) | 0.003 |
| MHAQ score (0–3) | 0.63±0.45 0.63 (0.25–0.88) | 0.69±0.52 0.63 (0.25–1.00) | 0.10¶ | −0.18 (−0.22 to −0.13) | −0.25 (−0.28 to −0.22) | 0.01§ | −0.18 (−0.22 to −0.14) | −0.25 (−0.27 to −0.22) | 0.005 |
| SF-36 PCS | 31.8±8.7 32 (26–38) | 31.2±9.3 31 (25–38) | 0.32§ | 3.9 (2.8 to 4.9) | 5.1 (4.5 to 5.7) | 0.05§ | 3.4 (2.4 to 4.4) | 5.3 (4.7 to 5.8) | 0.002 |
| Physical functioning | 53.8±22.6 56 (35–70) | 49.4±24.4 50 (30–70) | 0.001§ | 8.1 (5.7 to 10.5) | 9.8 (8.4 to 11.2) | 0.23§ | 7.3 (5.1 to 9.5) | 10.1 (8.8 to 11.4) | 0.04 |
| Role physical | 22.1±33.1 0 (0–25) | 18.3±30.0 0 (0–25) | 0.05¶ | 0 (0–25) | 0 (0–50) | 0.06¶ | 15.2 (11.1 to 19.3) | 20.0 (17.6 to 22.3) | 0.05 |
| Bodily pain | 33.5±16.8 32 (22–41) | 32.9±17.4 32 (22–41) | 0.38¶ | 9 (0–19) | 10 (0–29) | 0.001¶ | 10.6 (8.4 to 12.7) | 15.2 (13.9 to 16.4) | <0.001 |
| General health | 51.2±19.9 50 (37–67) | 52.5±19.9 50 (40–67) | 0.25§ | 1.9 (−0.1 to 3.9) | 3.5 (2.3 to 4.6) | 0.17§ | 1.5 (−0.4 to 3.4) | 3.6 (2.5 to 4.7) | 0.07 |
| SF-36 MCS | 46.4±11.6 47 (38–57) | 45.6±11.3 46 (37–54) | 0.21§ | 1.7 (0.4 to 2.7) | 2.7 (2.0 to 3.4) | 0.11§ | 2.0 (0.9 to 3.0) | 2.6 (1.9 to 3.2) | 0.36 |
| Vitality | 40.5±21.7 40 (25–55) | 40.1±20.5 40 (25–55) | 0.76§ | 5.0 (2.8 to 7.1) | 7.7 (6.4 to 9.1) | 0.04§ | 4.8 (2.7 to 6.9) | 7.8 (6.6 to 9.0) | 0.02 |
| Social functioning | 65.5±26.2 75 (50–88) | 64.8±25.8 63 (50–88) | 0.51¶ | 8.0 (5.3 to 10.6) | 9.2 (7.6 to 10.7) | 0.43§ | 7.3 (5.0 to 9.5) | 9.4 (8.1 to 10.7) | 0.11 |
| Role emotional | 52.2±42.4 67 (0–100) | 47.1±42.1 33 (0–100) | 0.04¶ | 0 (0–33) | 0 (0–33) | 0.09¶ | 9.5 (5.2 to 13.8) | 11.9 (9.5 to 14.4) | 0.34 |
| Mental health | 72.0±17.9 73 (64–84) | 69.9±18.4 72 (60–84) | 0.03¶ | 2.7 (1.1 to 4.3) | 4.6 (3.5 to 5.6) | 0.07§ | 3.3 (1.7 to 4.9) | 4.4 (3.4 to 5.3) | 0.25 |
| SF-6D | 0.60±0.12 0.58 (0.52–0.67) | 0.59±0.12 0.58 (0.52–0.67) | 0.22§ | 0.06 (0.04 to 0.07) | 0.08 (0.07 to 0.09) | 0.006§ | 0.05 (0.04 to 0.07) | 0.08 (0.07 to 0.09) | 0.001 |
↵* Values are mean±SD and median (interquartile range) for baseline values, and mean (95% CI) or median (interquartile range) for changes.
↵† ANCOVA with adjustment for age, sex and the respective baseline values testing PsA vs RA.
↵‡ Estimated marginal means.
↵§ Two-sample t test.
↵¶ Mann–Whitney U test.
MCS, mental components summary; MHAQ, Modified Health Assessment Questionnaire; PCS, physical components summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; VAS, visual analogue scale.